At Qlaris, our lead program is QLS-101, a novel topical ocular therapy that lowers intraocular pressure with a unique mechanism of action. QLS-101 is distinct from currently available therapies by lowering episcleral venous pressure (EVP) and improving outflow distal to the trabecular meshwork. This novel mechanism may enable the treatment of diseases where options remain limited, such as Normal Tension Glaucoma or Sturge-Weber Syndrome, and also provide an additive therapeutic option for patients requiring further efficacy for Primary Open Angle Glaucoma or in combination with Minimally-Invasive Glaucoma Surgery devices.
Location: United States, Massachusetts, Wellesley
Employees: 11-50
Total raised: $8.2M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 15.08.2020 | Canaan Par... | canaan.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.08.2019 | Series A | $8.2M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 30.04.2024 | Qlaris Bio Closes $24M Series B Financing | Qlaris Bio, a Dedham, MA-based clinical-stage biotechnology company, raised $24M in Series B funding... | finsmes.co... |
| - | Qlaris Bio | “Qlaris Bio” | fastfounde... |